Brightsurf Science News & Current Events

April 16, 2016
Public health concern as data reveals high prevalence of hepatitis B among refugees in Germany
A new study presented today demonstrates the potential challenge posed to public health systems across Europe as a result of the prevalence of hepatitis B among new refugee populations.

Heart attack patients more depressed but get less antidepressants
Heart attack patients are more depressed but are less often prescribed antidepressants than people who have not had a heart attack, according to research presented today at EuroHeartCare 2016 by Dr.

Disappointing data for diabetes drug in the treatment of non-alcoholic fatty liver disease
New data presented today at The International Liver Congress™ 2016 in Barcelona, Spain, demonstrates that the drug sitagliptin - more commonly used to treat diabetes - was no more effective than placebo for reducing non-alcoholic fatty liver disease.

Waist not weight -- the key to non-alcoholic fatty liver disease
A new study presented today demonstrates that a build-up of fat around the waist can cause more serious complications than obesity in the development of non-alcoholic fatty liver disease.

Sarcopenia, which affects up to 20 percent of European seniors, may increase 63 percent by 2045
Sarcopenia is a disease associated with the ageing process. Hallmark signs of the disorder are loss of muscle mass and strength, which in turn affects balance, gait and overall ability to perform tasks of daily living.

Investigational treatment provides hope for some chronic liver disease sufferers
A new study presented today provides hope for a new treatment in patients with primary sclerosing cholangitis, a rare condition characterized by inflammation and scarring in the bile ducts of the liver and for which there are currently no medicines.

Study shows hip fracture risk rises in the 10 years after total knee replacement
A Swedish study shows that individuals with total knee replacement (TKR) due to primary osteoarthritis had a low risk for hip and vertebral fracture in the decade before surgery.

Potential first-in-class treatment is well-tolerated in patients with chronic hepatitis B
New data presented today confirms that a novel first-in-class treatment for hepatitis B, called NVR 3-778, is well-tolerated and can reduce levels of the virus' genetic material in the body when combined with pegylated interferon after four weeks of treatment.

New study demonstrates efficacy of all-oral treatment regimens in adolescents with hepatitis C virus
Adolescents with Hepatitis C (HCV) could benefit from a combination of direct-acting antivirals, according to new data presented today at The International Liver Congress™ 2016 in Barcelona, Spain.

UK study supports cardiovascular safety of calcium and vitamin D supplementation
UK researchers have presented a new study that supports the cardiovascular safety of calcium and vitamin D supplementation.

Farmers are not just the backbone of a nation, they may have stronger hips too
This study found that in Sweden, for male farmers, the risk of a hip fracture was 14 percent lower compared to other occupations, adjusted for age.

Low-cost generic direct-acting antiviral treatment for hep C is equivalent to branded formulations
Data presented today demonstrates that generic direct-acting antivirals are as effective and safe as branded treatments to cure hepatitis C.

IOF President's Award presented to leading regional osteoporosis advocates
International Osteoporosis Foundation (IOF) President's Award was presented today to eight leading regional osteoporosis experts and advocates in recognition of their contributions to IOF and their extraordinary work in the field.

Tecnalia develops a bioadhesive gel for the treatment of diabetic foot ulcers
The College of Pharmacy of the University of Barcelona, Ojer Pharma Laboratories and Tecnalia are jointly collaborating on the project, PRODERMA: 'Coorperative Development of a Sustained Release Matrix for the Treatment of Diabetic Foot Ulcers.' The project seeks to improve the effectiveness of conventional topical treatments through the application of an innovative technique in the topical media and administration of active ingredients.

2016 AACR Annual Meeting presentations highlight advances in cancer DNA biomarker research using Bio-Rad's Droplet Digital PCR technology
DNA biomarkers are becoming 'powerful tools for predicting benefit from targeted therapies.' Droplet digital PCR technology is helping to realize this promise.

Engineering T cells to treat pancreatic cancer
Dr. Sunil Hingorani, a member of the Clinical Research and Public Health Sciences divisions at Fred Hutchinson Cancer Research Center, will present recent groundbreaking developments in treating pancreas cancer with engineered T-cells at the American Association for Cancer Research Annual Meeting 2016 in New Orleans on April 16.

Phase 2 data show treatment efficacy in 'difficult-to-cure' hepatitis C patients
A hepatitis C (HCV) drug currently under investigation, ABT-493 and ABT-530, which is an all-oral once-daily antiviral treatment, helped HCV genotype 3 patients with heavily scarred livers and no previous treatment history to achieve a 100 percent sustained virologic response after receiving the treatment for 12 weeks (SVR12).

New study challenges the concept of treatment failure in hepatitis C
Data presented today demonstrate that choosing a different combination of direct-acting antiviral (DAA) treatment for hepatitis C can eradicate the virus at four weeks in patients who had already failed on previous medication regimens.

Scientists find a way to cure hepatitis C with 6 weeks of treatment
A pilot study presented today found that all patients with acute HCV who were treated with a direct-acting antiviral treatment over a 'short-duration' of six weeks had undetectable HCV after a 12 week follow-up.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.